Agudo, J., Martin, M., Roca, C., Molas, M., Bura, A. S., Zimmer, A., Bosch, F. & Maldonado, R.
2010 Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 53, 2629-40.
Arendt, C. W., Albrecht, B., Soos, T. J. & Littman, D. R. 2002 Protein kinase C-theta;: signaling from the center of the T-cell synapse. Curr Opin Immunol 14, 323-30.
Baker, D., Pryce, G., Giovannoni, G. & Thompson, A. J. 2003 The therapeutic potential of cannabis. Lancet Neurol 2, 291-8.
Bauer, B., Krumbock, N., Ghaffari-Tabrizi, N., Kampfer, S., Villunger, A., Wilda, M., Hameister, H., Utermann, G., Leitges, M., Uberall, F. & Baier, G. 2000 T cell expressed PKCtheta demonstrates cell-type selective function. Eur J Immunol 30, 3645-54.
Beadling, C., Johnson, K. W. & Smith, K. A. 1993 Isolation of interleukin 2-induced immediate-early genes. Proc Natl Acad Sci U S A 90, 2719-23.
Bisogno, T., Melck, D., Bobrov, M., Gretskaya, N. M., Bezuglov, V. V., De Petrocellis, L. & Di Marzo, V. 2000 N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351 Pt 3, 817-24.
Borner, C., Hollt, V. & Kraus, J. 2007 Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation 14, 281-6.
Borner, C., Smida, M., Hollt, V., Schraven, B. & Kraus, J. 2009 Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem 284, 35450-60.
Buckley, N. E., McCoy, K. L., Mezey, E., Bonner, T., Zimmer, A., Felder, C. C., Glass, M. &
Zimmer, A. 2000 Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396, 141-9.
Carlisle, S. J., Marciano-Cabral, F., Staab, A., Ludwick, C. & Cabral, G. A. 2002 Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2, 69-82.
Cencioni, M. T., Chiurchiu, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L. &
Maccarrone, M. 2010 Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5, e8688.
Chen, W., Kaplan, B. L., Pike, S. T., Topper, L. A., Lichorobiec, N. R., Simmons, S. O., Ramabhadran, R. & Kaminski, N. E. 2012 Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120. J Leukoc Biol 92, 1093-102.
Literaturverzeichnis
Compton, D. R., Gold, L. H., Ward, S. J., Balster, R. L. & Martin, B. R. 1992 Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263, 1118-26.
Costantino, C. M., Gupta, A., Yewdall, A. W., Dale, B. M., Devi, L. A. & Chen, B. K. 2012 Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS One 7, e33961.
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A. & Gilula, N. B. 1996 Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-7.
De Filippis, D., D'Amico, A. & Iuvone, T. 2008 Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol 20 Suppl 1, 20-5.
Derocq, J. M., Segui, M., Marchand, J., Le Fur, G. & Casellas, P. 1995 Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369, 177-82.
Devane, W. A., Dysarz, F. A., 3rd, Johnson, M. R., Melvin, L. S. & Howlett, A. C. 1988 Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34, 605-13.
Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. & Mechoulam, R. 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-9.
Di Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A. & Kunos, G.
1999 Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264, 258-67.
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C. & Piomelli, D.
1994 Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-91.
Dinh, T. P., Kathuria, S. & Piomelli, D. 2004 RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66, 1260-4.
Dooms, H., Kahn, E., Knoechel, B. & Abbas, A. K. 2004 IL-2 induces a competitive survival advantage in T lymphocytes. J Immunol 172, 5973-9.
Dutil, E. M., Toker, A. & Newton, A. C. 1998 Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). Curr Biol 8, 1366-75.
Edgemond, W. S., Hillard, C. J., Falck, J. R., Kearn, C. S. & Campbell, W. B. 1998 Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54, 180-8.
Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M. & Leon, A. 2003 Cannabinoids
Literaturverzeichnis
Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L. &
Mitchell, R. L. 1995 Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48, 443-50.
Felder, C. C., Veluz, J. S., Williams, H. L., Briley, E. M. & Matsuda, L. A. 1992 Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42, 838-45.
Frank, D. A., Robertson, M. J., Bonni, A., Ritz, J. & Greenberg, M. E. 1995 Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A 92, 7779-83.
Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Jr., Lombard, L. A., Gray, G. S. & Nadler, L. M. 1993 Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262, 909-11.
Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G. & Casellas, P. 1995 Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232, 54-61.
Gaoni, Y., Mechoulam, R. 1964 Isolation, structure, and partial synthesis of an active constituent of hashish. . J Am Chem Soc 86, 1646-1647.
Garcia, D. E., Brown, S., Hille, B. & Mackie, K. 1998 Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 18, 2834-41.
Gardner, B., Zu, L. X., Sharma, S., Liu, Q., Makriyannis, A., Tashkin, D. P. & Dubinett, S. M.
2002 Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Commun 290, 91-6.
Glaser, S. T., Abumrad, N. A., Fatade, F., Kaczocha, M., Studholme, K. M. & Deutsch, D. G.
2003 Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100, 4269-74.
Gong, D. & Malek, T. R. 2007 Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J Immunol 178, 242-52.
Gordon, J. & MacLean, L. D. 1965 A lymphocyte-stimulating factor produced in vitro. Nature 208, 795-6.
Granucci, F., Vizzardelli, C., Pavelka, N., Feau, S., Persico, M., Virzi, E., Rescigno, M., Moro, G.
& Ricciardi-Castagnoli, P. 2001 Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2, 882-8.
Greenfield, E. A., Nguyen, K. A. & Kuchroo, V. K. 1998 CD28/B7 costimulation: a review. Crit Rev Immunol 18, 389-418.
Hasseldam, H. & Johansen, F. F. 2010 Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis.
Neuroimmunomodulation 17, 252-64.
Literaturverzeichnis
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R. & Rice, K. C. 1990 Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87, 1932-6.
Hillard, C. J. & Auchampach, J. A. 1994 In vitro activation of brain protein kinase C by the cannabinoids. Biochim Biophys Acta 1220, 163-70.
Hodge, D. L., Martinez, A., Julias, J. G., Taylor, L. S. & Young, H. A. 2002 Regulation of nuclear gamma interferon gene expression by interleukin 12 (IL-12) and IL-2 represents a novel form of posttranscriptional control. Mol Cell Biol 22, 1742-53.
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E. & Porrino, L.
J. 2004 Cannabinoid physiology and pharmacology: 30 years of progress.
Neuropharmacology 47 Suppl 1, 345-58.
Hoyer, K. K., Dooms, H., Barron, L. & Abbas, A. K. 2008 Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 226, 19-28.
Huang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., Miller, J. D., Davies, S. N., Geppetti, P., Walker, J. M. & Di Marzo, V. 2002 An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99, 8400-5.
Jan, T. R. & Kaminski, N. E. 2001 Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J Leukoc Biol 69, 841-9.
Jan, T. R., Rao, G. K. & Kaminski, N. E. 2002 Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol Pharmacol 61, 446-54.
Johns, D. G., Behm, D. J., Walker, D. J., Ao, Z., Shapland, E. M., Daniels, D. A., Riddick, M., Dowell, S., Staton, P. C., Green, P., Shabon, U., Bao, W., Aiyar, N., Yue, T. L., Brown, A. J., Morrison, A. D. & Douglas, S. A. 2007 The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152, 825-31.
Jorgensen, K. A., Koefoed-Nielsen, P. B. & Karamperis, N. 2003 Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 57, 93-8.
Juel-Jensen, B. E. 1972 Cannabis and recurrent herpes simplex. Br Med J 4, 296.
Karin, M. & Delhase, M. 2000 The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 12, 85-98.
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L. & Friedman, H. 2003 The cannabinoid system and immune modulation. J Leukoc Biol 74, 486-96.
Klein, T. W., Newton, C. A., Nakachi, N. & Friedman, H. 2000 Delta 9-tetrahydrocannabinol
Literaturverzeichnis
Kozak, K. R., Crews, B. C., Morrow, J. D., Wang, L. H., Ma, Y. H., Weinander, R., Jakobsson, P. J. & Marnett, L. J. 2002 Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277, 44877-85.
Laemmli, U. K. 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-5.
LeCapitaine, N. J., Zhang, P., Winsauer, P., Walker, E., Vande Stouwe, C., Porretta, C. &
Molina, P. E. 2011 Chronic Delta-9-tetrahydrocannabinol administration increases lymphocyte CXCR4 expression in rhesus macaques. J Neuroimmune Pharmacol 6, 540-5.
Lee, S. F., Newton, C., Widen, R., Friedman, H. & Klein, T. W. 2001 Downregulation of cannabinoid receptor 2 (CB2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. Adv Exp Med Biol 493, 223-8.
Leo, A. & Schraven, B. 2001 Adapters in lymphocyte signalling. Curr Opin Immunol 13, 307-16.
Li, Y. Y., Yuece, B., Cao, H. M., Lin, H. X., Lv, S., Chen, J. C., Ochs, S., Sibaev, A., Deindl, E., Schaefer, C. & Storr, M. 2013 Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. Lab Invest 93, 322-33.
Lombard, C., Hegde, V. L., Nagarkatti, M. & Nagarkatti, P. S. 2011 Perinatal exposure to Delta9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens. J Pharmacol Exp Ther 339, 607-17.
Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A. &
Rosenberg, S. A. 1986 Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58, 2764-72.
Maccarrone, M., De Petrocellis, L., Bari, M., Fezza, F., Salvati, S., Di Marzo, V. & Finazzi-Agro, A. 2001 Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 393, 321-8.
Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A. 2000 Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275, 31938-45.
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutierrez, S. O., van der Stelt, M., Lopez-Rodriguez, M. L., Casanova, E., Schutz, G., Zieglgansberger, W., Di Marzo, V., Behl, C. & Lutz, B. 2003 CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-8.
Matias, I., Pochard, P., Orlando, P., Salzet, M., Pestel, J. & Di Marzo, V. 2002 Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269, 3771-8.
Literaturverzeichnis
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-4.
McKallip, R. J., Lombard, C., Fisher, M., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, P. S. &
Nagarkatti, M. 2002 Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-34.
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R. & et al. 1995 Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50, 83-90.
Meuer, S. C., Acuto, O., Hussey, R. E., Hodgdon, J. C., Fitzgerald, K. A., Schlossman, S. F. &
Reinherz, E. L. 1983 Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor. Nature 303, 808-10.
Moon, J. J., Rubio, E. D., Martino, A., Krumm, A. & Nelson, B. H. 2004 A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor. J Biol Chem 279, 5520-7.
Munro, S., Thomas, K. L. & Abu-Shaar, M. 1993 Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-5.
Mustelin, T. 1994 T cell antigen receptor signaling: three families of tyrosine kinases and a phosphatase. Immunity 1, 351-6.
Mustelin, T., Coggeshall, K. M., Isakov, N. & Altman, A. 1990 T cell antigen receptor-mediated activation of phospholipase C requires tyrosine phosphorylation. Science 247, 1584-7.
Nakano, Y., Pross, S. & Friedman, H. 1993 Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages. Life Sci 52, 41-51.
Pandey, R., Mousawy, K., Nagarkatti, M. & Nagarkatti, P. 2009 Endocannabinoids and immune regulation. Pharmacol Res 60, 85-92.
Patwardhan, A. M., Jeske, N. A., Price, T. J., Gamper, N., Akopian, A. N. & Hargreaves, K. M.
2006 The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A 103, 11393-8.
Piomelli, D. 2003 The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-84.
Porter, A. C., Sauer, J. M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., Nomikos, G.
G., Carter, P., Bymaster, F. P., Leese, A. B. & Felder, C. C. 2002 Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301, 1020-4.
Pryce, G. & Baker, D. 2007 Control of spasticity in a multiple sclerosis model is mediated by
Literaturverzeichnis
Rao, A., Luo, C. & Hogan, P. G. 1997 Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15, 707-47.
Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, M. L., Sakai, M., Costa-Pinto, F. A. & Palermo-Neto, J. 2010 Anandamide prior to sensitization increases cell-mediated immunity in mice. Int Immunopharmacol 10, 431-9.
Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D. & et al. 1994 SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350, 240-4.
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Breliere, J. C. & Le Fur, G. L. 1998 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284, 644-50.
Rincon, M., Flavell, R. A. & Davis, R. J. 2001 Signal transduction by MAP kinases in T lymphocytes. Oncogene 20, 2490-7.
Rockwell, C. E. & Kaminski, N. E. 2004 A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 311, 683-90.
Rockwell, C. E., Snider, N. T., Thompson, J. T., Vanden Heuvel, J. P. & Kaminski, N. E. 2006 Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2.
Mol Pharmacol 70, 101-11.
Russell, S. M., Johnston, J. A., Noguchi, M., Kawamura, M., Bacon, C. M., Friedmann, M., Berg, M., McVicar, D. W., Witthuhn, B. A., Silvennoinen, O. & et al. 1994 Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.
Science 266, 1042-5.
Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N. O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T. & Greasley, P. J. 2007 The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152, 1092-101.
Saario, S. M., Savinainen, J. R., Laitinen, J. T., Jarvinen, T. & Niemi, R. 2004 Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 67, 1381-7.
Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C. & Horak, I. 1993 Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-61.
Sakaguchi, S. 2004 Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22, 531-62.
Salzet, M., Breton, C., Bisogno, T. & Di Marzo, V. 2000 Comparative biology of the endocannabinoid system possible role in the immune response. Eur J Biochem 267, 4917-27.
Literaturverzeichnis
Sarker, K. P. & Maruyama, I. 2003 Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell Mol Life Sci 60, 1200-8.
Schorle, H., Holtschke, T., Hunig, T., Schimpl, A. & Horak, I. 1991 Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352, 621-4.
Singh, U. P., Singh, N. P., Singh, B., Price, R. L., Nagarkatti, M. & Nagarkatti, P. S. 2012 Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 258, 256-67.
Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D. & Davis, J. B. 2000 The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129, 227-30.
Stern, J. B. & Smith, K. A. 1986 Interleukin-2 induction of T-cell G1 progression and c-myb expression. Science 233, 203-6.
Struwe, M., Kaempfer, S. H., Geiger, C. J., Pavia, A. T., Plasse, T. F., Shepard, K. V., Ries, K.
& Evans, T. G. 1993 Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27, 827-31.
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. & Waku, K. 1995 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215, 89-97.
Svendsen, K. B., Jensen, T. S. & Bach, F. W. 2004 Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Bmj 329, 253.
Tanasescu, R. & Constantinescu, C. S. 2010 Cannabinoids and the immune system: an overview. Immunobiology 215, 588-97.
Tauber, S., Paulsen, K., Wolf, S., Synwoldt, P., Pahl, A., Schneider-Stock, R. & Ullrich, O. 2012 Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors. PLoS One 7, e48272.
Tiburu, E. K., Bass, C. E., Struppe, J. O., Lorigan, G. A., Avraham, S. & Avraham, H. K. 2007 Structural divergence among cannabinoids influences membrane dynamics: a 2H solid-state NMR analysis. Biochim Biophys Acta 1768, 2049-59.
Towbin, H., Staehelin, T. & Gordon, J. 1979 Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76, 4350-4.
Truneh, A., Albert, F., Golstein, P. & Schmitt-Verhulst, A. M. 1985 Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 313, 318-20.
Literaturverzeichnis
Tsou, K., Brown, S., Sanudo-Pena, M. C., Mackie, K. & Walker, J. M. 1998 Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411.
Ullrich, O., Merker, K., Timm, J. & Tauber, S. 2007 Immune control by endocannabinoids - new mechanisms of neuroprotection? J Neuroimmunol 184, 127-35.
Villarino, A. V., Tato, C. M., Stumhofer, J. S., Yao, Z., Cui, Y. K., Hennighausen, L., O'Shea, J.
J. & Hunter, C. A. 2007 Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med 204, 65-71.
Wade, D. T., Makela, P., Robson, P., House, H. & Bateman, C. 2004 Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10, 434-41.
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K. & Stella, N. 2003 Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23, 1398-405.
Walter, L. & Stella, N. 2004 Cannabinoids and neuroinflammation. Br J Pharmacol 141, 775-85.
Wang, X., Dow-Edwards, D., Keller, E. & Hurd, Y. L. 2003 Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 118, 681-94.
Weissman, A. M., Baniyash, M., Hou, D., Samelson, L. E., Burgess, W. H. & Klausner, R. D.
1988 Molecular cloning of the zeta chain of the T cell antigen receptor. Science 239, 1018-21.
Yui, M. A., Sharp, L. L., Havran, W. L. & Rothenberg, E. V. 2004 Preferential activation of an IL-2 regulatory sequence transgene in TCR gamma delta and NKT cells: subset-specific differences in IL-2 regulation. J Immunol 172, 4691-9.
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. & Bonner, T. I. 1999 Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.
Proc Natl Acad Sci U S A 96, 5780-5.
Zmuidzinas, A., Mamon, H. J., Roberts, T. M. & Smith, K. A. 1991 Interleukin-2-triggered Raf-1 expression, phosphorylation, and associated kinase activity increase through G1 and S in CD3-stimulated primary human T cells. Mol Cell Biol 11, 2794-803.
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D. & Hogestatt, E. D. 1999 Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-7.
Danksagungen